A Pilot Study of Midomafetamine (MDMA-Assisted) Therapy for the Treatment of Pathological Narcissism
This open-label, proof-of-concept pilot study will assess the efficacy and safety of midomafetamine (MDMA) - assisted therapy (AT) for participants diagnosed with pathological narcissism. As all participants will be allocated to a single group assignment, there will be no blinding, randomization, or comparator treatment. Participants will have a screening visit, a preparation period of 3 visits, a treatment period receiving MDMA-AT at 3 monthly visits, a 6 month follow up period coming in at one week, one month, three months and six months after last treatment visit.
- Status
- active
- Phase
- Early Phase 1
- Institution
- University of Washington
- Principal investigator
- Anthony Back, MD
- Start date
- 2024-08-27
- End date
- 2027-01-31
- Registry ID
- NCT06565494
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.